MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Protara Therapeutics, Inc.(NASDAQ:TARA)*, formerly, Proteon Therapeutics, Inc.
Organization & Developments: Protara
Parents
Protara Therapeutics, Inc.(NASDAQ:TARA)*, formerly, Proteon Therapeutics, Inc.
Children
*Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
*Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease
*Proteon Therapeutics is a biotechnology company developing novel, first-in-class pharmaceuticals to address kidney and vascular diseases
2019: Proteon's vonapanitase flunks second late-stage study_seekingalpha.com
2019: The new company was form when Proteon Therapeutics merged with privately held ArTara Therapeutics in late 2019
2020: Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases.
2021: Our First Look At Protara Therapeutics
2022: Protara Therapeutics (TARA) Investor Presentation - Slideshow_seekingalpha.com
2022: The Prognosis For Protara Therapeutics_seekingalpha.com
2024: Protara shares spike after cell therapy shows high response rate, no severe side effects in bladder cancer trial
2024: Protara Therapeutics Launches Massive $100M Public Offering to Advance TARA-002 Development
2024: Protara Therapeutics: Carving New Roads In Bladder Cancer_seekingalpha.com
2024: Protara Therapeutics: Rising From The Ashes
2024: Protara, CG Oncology Tout Promising Bladder Cancer Outcomes
2024: Protara: A Bombed Out Biotech With A Very Positive Skew
2024: Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst_seekingalpha.com
2025: Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025
Jumps
Finance & Acquisitions: Protara
Key People: Protara